232 related articles for article (PubMed ID: 27425822)
1. Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
Lin J; Chang JS; Smiddy WE
Ophthalmology; 2016 Sep; 123(9):1912-8. PubMed ID: 27425822
[TBL] [Abstract][Full Text] [Related]
2. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
Lin J; Chang JS; Yannuzzi NA; Smiddy WE
Ophthalmology; 2018 Sep; 125(9):1393-1400. PubMed ID: 29606379
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
[TBL] [Abstract][Full Text] [Related]
5. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial.
Figueira J; Silva R; Henriques J; Caldeira Rosa P; Laíns I; Melo P; Gonçalves Nunes S; Cunha-Vaz J
Ophthalmologica; 2016; 235(1):34-41. PubMed ID: 26630400
[TBL] [Abstract][Full Text] [Related]
7. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
Brown GC; Brown MM; Turpcu A; Rajput Y
Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
Haig J; Barbeau M; Ferreira A
J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
[TBL] [Abstract][Full Text] [Related]
10. Cost-Utility of Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Lin J; Gibbons A; Smiddy WE
Ophthalmol Retina; 2021 Jul; 5(7):656-663. PubMed ID: 33002672
[TBL] [Abstract][Full Text] [Related]
11. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
Messias K; Barroso RM; Jorge R; Messias A
Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
13. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.
Filho JA; Messias A; Almeida FP; Ribeiro JA; Costa RA; Scott IU; Jorge R
Acta Ophthalmol; 2011 Nov; 89(7):e567-72. PubMed ID: 21726427
[TBL] [Abstract][Full Text] [Related]
14. Proliferative diabetic retinopathy treated with intravitreal ranibizumab and photocoagulation directed at ischemic retinal areas-A randomized study.
Toscano L; Messias A; Messias K; de Cenço Lopes R; Ribeiro JAS; Scott IU; Jorge R
Doc Ophthalmol; 2021 Dec; 143(3):313-322. PubMed ID: 34347216
[TBL] [Abstract][Full Text] [Related]
15. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.
Messias A; Ramos Filho JA; Messias K; Almeida FP; Costa RA; Scott IU; Gekeler F; Jorge R
Doc Ophthalmol; 2012 Jun; 124(3):225-36. PubMed ID: 22457045
[TBL] [Abstract][Full Text] [Related]
16. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.
Beaulieu WT; Bressler NM; Melia M; Owsley C; Mein CE; Gross JG; Jampol LM; Glassman AR;
Am J Ophthalmol; 2016 Oct; 170():206-213. PubMed ID: 27523491
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and panretinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea.
Lee HJ; Cho S; Park J; Jin Y; Kim HM; Jee D
BMC Health Serv Res; 2023 Dec; 23(1):1388. PubMed ID: 38082399
[TBL] [Abstract][Full Text] [Related]
18. Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy.
Azad AD; Chen EM; Hinkle J; Rayess N; Wu D; Eliott D; Mruthyunjaya P; Parikh R
Ophthalmol Retina; 2021 Feb; 5(2):151-159. PubMed ID: 32693033
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications of cost analysis of diabetic macular edema treatments.
Smiddy WE
Ophthalmology; 2012 Dec; 119(12):2558-62. PubMed ID: 23062655
[TBL] [Abstract][Full Text] [Related]
20. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
